Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation
The clinical development of this combination strategy was discontinued, as brigatinib treatment was not feasible in patients with advanced EGFR-mutated NSCLC resistant to osimertinib.
Authors
- Hibiki Udagawa (ORCID: https://orcid.org/0000-0001-8822-2684)
- Yoshitaka Zenke (ORCID: https://orcid.org/0000-0002-7641-9065)
- Ken Uchibori (ORCID: https://orcid.org/0000-0003-1491-923X)
- Koichi Goto
- Shogo Nomura
- Jun Sakakibara-Konishi
- Yuji Shibata
- Tomohiro Sakamoto
- Hiroki Izumi
- Kaname Nosaki
- Tetsuya Sakai
- Seiji Niho
- Kazumi Nishino
- Kiyotaka Yoh
- Ryohei Katayama
- Shingo Matsumoto
Institutions
- Chemotherapy Foundation (US)
- The Cancer Institute Hospital (JP)
- Japan Society of Chemotherapy (JP)
- Hokkaido University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Osaka International Cancer Institute (JP)
- Tottori University (JP)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2026.101105
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00